Metronidazol B. Braun (Metronidazole)

Metronidazole is reduced inside anaerobic microorganisms to form nitro radical anions. These reactive species damage bacterial DNA and inhibit nucleic acid synthesis, leading to cell death while having minimal effect on aerobic cells.

The dosage and infusion rate of Metronidazol B. Braun are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines.

Safety data for metronidazole in pregnancy are limited and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the potential risk to the fetus. Caution is also advised during breastfeeding, and a healthcare professional should evaluate the risk‑benefit ratio.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Metronidazol B. Braun delivers the same active ingredient as other metronidazole products but in an injectable form, allowing rapid systemic exposure for severe infections. Compared with oral formulations, the IV route provides higher plasma concentrations, which can be advantageous in critically ill patients or when oral absorption is compromised.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, inspect the solution for particulate matter and ensure the vial is within its expiry date.

Metronidazol B. Braun is administered by intravenous infusion. The solution is typically diluted in compatible IV fluids and infused over a period dictated by the prescribing clinician, taking into account the infection severity and patient tolerance.

Serious risks include severe allergic reactions such as anaphylaxis, seizures, peripheral neuropathy, and hepatic dysfunction. Patients should be monitored for signs of these events, and treatment should be discontinued immediately if they occur.

Metronidazol B. Braun is contraindicated in patients with a known hypersensitivity to metronidazole or any component of the formulation. Caution is also advised in individuals with severe hepatic impairment, and it should be avoided in patients who are actively consuming alcohol due to the risk of a disulfiram‑like reaction.